Exploiting the hallmarks of cancer: the future conquest of breast cancer (Q35187835)

7 August 2017

1 reference

title

Exploiting the hallmarks of cancer: the future conquest of breast cancer (English)

1 reference

7 August 2017

1 reference

Sledge GW Jr

1

1 reference

7 August 2017

Miller KD

series ordinal

2

1 reference

7 August 2017

publication date

1 August 2003

1 reference

European Journal of Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

39

1 reference

7 August 2017

issue

12

1 reference

7 August 2017

page(s)

1668-1675

1 reference

7 August 2017

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Transforming growth factor alpha and mouse models of human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

IGF-1 receptor as the restriction point of the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Insulin-like growth factors: the unrecognised oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

The GH-IGF-I axis and breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Octreotide as first-line treatment for women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Cyclin D1, retinoblastoma, p53, and Her2/neu protein expression in preinvasive breast pathologies: correlation with vascularity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Cyclin E and survival in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

p(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Telomerase and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Telomerase activity in ductal carcinoma in situ of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Telomerase activity and lymphovascular invasion in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Telomerase inhibition by induced expression of antisense RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Mutant p53 and genomic instability in a transgenic mouse model of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: A pathway to metastatic progression in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900273-9

7 January 2021

10.1016/S0959-8049(03)00273-9

Identifiers

DOI

1 reference

7 August 2017

1 reference